Healthcare Cooperative. Testing HIV on a dime. Public release date: 29-Mar-2011 [ Print | E-mail Share ] [ Close Window ] Contact: Caroline McCallcmccall5@mit.edu Massachusetts Institute of Technology CAMBRIDGE, Mass. -- A Harvard bioengineer and an MIT aeronautical engineer have created a new device that can detect single cancer cells in a blood sample, potentially allowing doctors to quickly determine whether cancer has spread from its original site. The microfluidic device, described in the March 17 online edition of the journal Small, is about the size of a dime, and could also detect viruses such as HIV. It could eventually be developed into low-cost tests for doctors to use in developing countries where expensive diagnostic equipment is hard to come by, says Mehmet Toner, professor of biomedical engineering at Harvard Medical School and a member of the Harvard-MIT Division of Health Sciences and Technology.
Toner built an earlier version of the device four years ago. . [ Print | E-mail AAAS and EurekAlert!
Microsponges from seaweed may save lives. Public release date: 9-Feb-2011 [ Print | E-mail Share ] [ Close Window ] Contact: David Ruthdruth@rice.edu 713-348-6327Rice University Microsponges derived from seaweed may help diagnose heart disease, cancers, HIV and other diseases quickly and at far lower cost than current clinical methods. The microsponges are an essential component of Rice University's Programmable Bio-Nano-Chip (PBNC) and the focus of a new paper in the journal Small.
The paper by John McDevitt, the Brown-Wiess Professor in Bioengineering and Chemistry, and his colleagues at Rice's BioScience Research Collaborative views the inner workings of PBNCs, which McDevitt envisions as a mainstream medical diagnostic tool. PBNCs to diagnose a variety of diseases are currently the focus of six human clinical trials. McDevitt will discuss their development at the annual meeting of the American Association for the Advancement of Science (AAAS) in Washington, D.C., Feb. 17-21. [ Print | E-mail AAAS and EurekAlert!
- Drug Information Association. GO From the Editor's Desk April 2014 Global Forum Now Online: The US National Institutes of Health estimates that there are approximately 6,000 rare diseases affecting 25 million Americans. EURORDIS, the Voice of Rare Disease Patients in Europe, estimates the number of persons in Europe suffering from a rare disease at over 30 million. This Special Section Orphan Drugs in the 21st Century explores different strategies and pathways to meet the needs of patients around the world with rare diseases, including an interview with the Director of the FDA Office of Orphan Product Development. Also Featured: Our interview with DIA 2014 50th Annual Meeting Keynote Speaker Jamie Heywood, and previews of our 6th Latin American Regulatory Conference: LARC 2014 and our 8th Annual Conference in Japan for Asian New Drug Development.
Read the April issue. Guest Commentary: Therapeutic Innovation & Regulatory Science - March 2014 Read full commentary. Read more TIRS articles. NEW! June 15-19 | San Diego, CA. Partners Harvard Medical International - The Global Leader in Transforming Health Care and Education.
TV on Demand - Association Video Magazines - Internet Streaming TV. Host: Kristine Mighion, MD, MBA Guest: Kate Liebelt - President, Chicago Health Executives Forum (CHEF) Guest 2: Chet Szerlag - Past President, Chicago Health Executives Forum (CHEF) Guest 3: Katie Carow - Education and Networking Chair, Chicago Health Executives Forum (CHEF) Topic: Implementing the Balanced Scorecard in the Provider Setting (flv) Host: Kristine Mighion, MD, MBA Guest: Geoff Colgan, Managing Director, Attadale Partners Topic: Chicago Health Executives Forum: Past, Present & Future (flv) Host: Kristine Mighion, MD, MBA Guest: Wayne Lerner, President & CEO, Holy Cross Hospital Guest 2: Gary Kaatz, President & CEO, Rockford Health System Topic: Designed to Adapt: Leading Healthcare in Challenging Times (flv) Host: Kristine Mighion, MD, MBA Guest: John W.
Kenagy, MD, MPA, ScD, FACS - Author, "Designed To Adapt" Topic: The Importance of Transparency (flv) Host: Kristine Mighion, MD, MBA Guest: Larry Boress - Midwest Business Group on Health Windows Media Player is (wmf). Science. The more we understand about science and its complexities, the more important it is for scientific data to be shared openly. It’s not useful to have ten different labs doing the same research and not sharing their results; likewise, we’re much more likely to be able to pinpoint diseases if we have genomic data from a large pool of individuals. Since 2004, we’ve been focusing our efforts to expand the use of Creative Commons licenses to scientific and technical research.
Science Advisory Board Open Access The Scholars’ Copyright Project Creative Commons plays an instrumental role in the Open Access movement, which is making scholarly research and journals more widely available on the Web. We’re also expanding Open Access to research institutions. We’ve created policy briefings and guidelines to help institutions implement Open Access into their frameworks. Open Data At Creative Commons, we believe scientific data should be freely available to everyone. Learn more. NCI Alliance for Nanotechnology in Cancer. Gene Therapy. Cellular & Gene Therapy Products. The Center for Biologics Evaluation and Research (CBER) regulates cellular therapy products, human gene therapy products, and certain devices related to cell and gene therapy.
CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight. Cellular therapy products include cellular immunotherapies, and other types of both autologous and allogeneic cells for certain therapeutic indications, including adult and embryonic stem cells. Human gene therapy refers to products that introduce genetic material into a person’s DNA to replace faulty or missing genetic material, thus treating a disease or abnormal medical condition. Although some cellular therapy products have been approved, CBER has not yet approved any human gene therapy product for sale. Home.
Creating Infrastructure and Demand for Mobile Health Apps Our applications and services that are revolutionizing mobile health: AppScript™: SaaS solution evaluates 40,000+ apps, enabling physicians to make confident, effective mHealth prescribing decisions AppNucleus™: secure app development platform to support next wave of secure app development Click here to learn more » Flip Real-World Evidence.
Patients’ journeys through the healthcare system are complex, crossing multiple care settings and often comprising multiple diseases and treatments. Real-world evidence shows how treatments perform in the real world, beyond what we see in an artificial clinical trial environment. Click here to learn more » Achieve Clarity and Confidence with Data Driven Insight Plan, manage and lead the clinical trial process with real-time insights: Feasible protocol development Reliable country and site selection Optimal enrollment plans Predictable financial outlays Actionable insights Click here to learn more »
Home | cafepharma. Health-Care Reform 2010 - Tracking the National Health-Care Debate. Special report: Financially sick hospital syndrome. This report originally appeared in the October 2010 issue of DOTmed Business News As a favor to a friend, John Baran, a retired PricewaterhouseCoopers partner, sat in on an Auburn Memorial Hospital board meeting to take a look at its financial situation. What he saw wasn’t pretty. Story Continues Below Advertisement Ad Statistics Times Displayed: 3256447 Times Visited: 7946 OiService - ISO 9001 & 13485 Certified - Call 888-673-5151 Oxford Instruments Service, is a leading ISO 9001 & 13485-certified organization,that specializes in providing quality after-market GE CT and MRI systems, serviceand parts - at prices you can afford.
“I saw the place was underwater,” Baran recalls. Baran accepted the position of CFO for the Auburn, N.Y. “We knew going in, that our strongest asset was the fact that we were the only hospital in town,” says Baran. In April 2007, the hospital filed for bankruptcy, ironically the first step in pulling itself up by its bootstraps. How did we get here?